UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore Not applicable (State or other jurisdiction ...

WAVE | --- | --- | --- | --- | --- | --- | --- | |----------------------------|--------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | Third Quarter 2021 | Wave Life Sciences | | | | | | | Earnings November 10, 2021 | | | | | | | Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operatio ...

Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2021 Earnings Conference Call November 10, 2021 8:30 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President & Chief Executive Officer Chandra Vargeese - Chief Technology Officer Mike Panzara - Chief Medical Officer, Head of Therapeutics Discovery & Development Kyle Moran - Chief Financial Officer Conference Call Participants Salim Syed - Mizuho Mehdi Goudarzi - Truist Luca Issi - RBC Capital Operator Good morning and welcome to the ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37627 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore (State or other j ...

Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update August 5, 2021 Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD – first oligonucleotide using PN backbone chemistry modifications in clinical study Recruitment ongoing for clinical trials in HD and DMD Generating clinical data in multiple trials through 2022 to enable decision making Leading endogenous ADAR editing capability demonstrated restoration of functional AAT protein in vivo; new da ...

Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President & Chief Executive Officer Mike Panzara - Chief Medical Officer Head, Therapeutics Discovery & Development Paloma Giangrande - Vice President, Platform and Discovery Sciences & Biology Kyle Moran - Chief Financial Officer Conference Call Participants Mehdi Goudarzi - Truist Salim Syed - Mizuho Alex Thompson - Stifel Operator Good m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) | Singapore | Not applicable | | ...

| --- | --- | --- | --- | --- | --- | --- | |-------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | Wave Life Sciences | | | | | | | | Corporate Presentation May 13, 2021 | | | | | | | Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and ...

Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2021 Earnings Conference Call May 13, 2021 8:30 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President & Chief Executive Officer Mike Panzara - Chief Medical Officer, Head of Therapeutics Discovery & Development Kyle Moran - Chief Financial Officer Conference Call Participants Michael Lin - Mizuho Joon Lee - Truist Mani Foroohar - SVB Leerink Eun Yang - Jefferies Operator Good morning and welcome to the Wave Life Sciences First Quar ...

Wave Life Sciences First Quarter 2021 Earnings May 13, 2021 Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing thereof, competitive position, potential growth oppor ...